Literature DB >> 23416850

A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.

Doris M Ponce1, Craig Sauter, Sean Devlin, Marissa Lubin, Anne Marie Gonzales, Nancy A Kernan, Andromachi Scaradavou, Sergio Giralt, Jenna D Goldberg, Guenther Koehne, Miguel A Perales, James W Young, Hugo Castro-Malaspina, Ann Jakubowski, Esperanza B Papadopoulos, Juliet N Barker.   

Abstract

A preparative regimen of reduced intensity that can reliably engraft cord blood (CB) and can be used as an alternative to either high-dose myeloablative or nonmyeloablative conditioning is needed. We evaluated double-unit CB transplantation in 30 patients (median age, 56 years; range, 18 to 69) with acute leukemia or myelodysplasia using a regimen of cyclophosphamide 50 mg/kg, fludarabine 150 mg/m(2), thiotepa 10 mg/kg, and 400 cGy total body irradiation with cyclosporine-A/mycophenolate mofetil immunosuppression. Ninety-seven percent of patients engrafted at a median of 26 days (range, 13 to 43), and 93% of patients had recovered platelets by day 180. Grades II to IV acute graft-versus-host disease (GVHD) incidence was 67% at day 180, and chronic GVHD was 10% at 1 year. Transplant-related mortality was 20% at day 180, and relapse was 11% at 2 years. Overall, 2-year disease-free survival (DFS) was 60% at 2 years. A hierarchy in DFS was seen according to the Sorror comorbidity score: 11 patients (median age, 55 years) with a score of 1 had a 2-year DFS of 82% compared with 62% in 9 patients (median age, 51 years) with a score of 2 to 3 and 40% in 11 patients (median age, 58 years) with a score of 4 to 5 (P = .13). This reduced-intensity regimen combined with double-unit CB transplantation reliably facilitates sustained donor engraftment without antithymocyte globulin. Although other approaches are needed in patients with high comorbidity scores, this regimen is highly effective in patients ≥50 years old who are otherwise reasonably fit. It also represents a promising alternative to high-dose conditioning in younger patients.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23416850      PMCID: PMC3673764          DOI: 10.1016/j.bbmt.2013.02.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  32 in total

1.  Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study.

Authors:  Roberto Raimondi; Alberto Tosetto; Rosi Oneto; Riccardo Cavazzina; Francesco Rodeghiero; Andrea Bacigalupo; Renato Fanin; Alessandro Rambaldi; Alberto Bosi
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

2.  Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning.

Authors:  Jonathan Cohen; Minal Gandhi; Paru Naik; David Cubitt; Kanchan Rao; Urvashi Thaker; E Graham Davies; H Bobby Gaspar; Persis J Amrolia; Paul Veys
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

3.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

4.  Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.

Authors:  Claudio G Brunstein; Daniel J Weisdorf; Todd DeFor; Juliet N Barker; Jakub Tolar; Jo-Anne H van Burik; John E Wagner
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

5.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

6.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Jeffrey S Miller; John E Wagner
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

7.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Philip B McGlave; Jeffrey S Miller; Catherine M Verfaillie; John E Wagner
Journal:  Blood       Date:  2004-10-05       Impact factor: 22.113

8.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Authors:  Claudio G Brunstein; Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; John E Wagner
Journal:  Blood       Date:  2007-06-14       Impact factor: 22.113

9.  Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases.

Authors:  Naoyuki Uchida; Atsushi Wake; Shinsuke Takagi; Hisashi Yamamoto; Daisuke Kato; Yoshiko Matsuhashi; Tomoko Matsumura; Sachiko Seo; Naofumi Matsuno; Kazuhiro Masuoka; Eiji Kusumi; Koichiro Yuji; Shigesaburo Miyakoshi; Michio Matsuzaki; Akiko Yoneyama; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

10.  Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.

Authors:  Christopher N Bredeson; Mei-Jie Zhang; Manza-A Agovi; Andrea Bacigalupo; Nizar J Bahlis; Karen Ballen; Christopher Brown; M Ahsan Chaudhry; Mary M Horowitz; Seira Kurian; Diana Quinlan; Catherine E Muehlenbien; James A Russell; Lynn Savoie; J Douglas Rizzo; Douglas A Stewart
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

View more
  37 in total

1.  Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies.

Authors:  Gunjan L Shah; Leyla Shune; Duncan Purtill; Sean Devlin; Emily Lauer; Marissa Lubin; Valkal Bhatt; Courtney McElrath; Nancy A Kernan; Andromachi Scaradavou; Sergio Giralt; Miguel A Perales; Doris M Ponce; James W Young; Monica Shah; Genovefa Papanicolaou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-10       Impact factor: 5.742

Review 2.  Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.

Authors:  Y S Jethava; S Sica; B Savani; F Socola; M Jagasia; M Mohty; A Nagler; A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2017-05-15       Impact factor: 5.483

3.  Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation.

Authors:  J A Gutman; K Ross; C Smith; H Myint; C-K Lee; R Salit; F Milano; C Delaney; D Gao; D A Pollyea
Journal:  Bone Marrow Transplant       Date:  2016-07-11       Impact factor: 5.483

4.  Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.

Authors:  H-L Liu; Z-M Sun; L-Q Geng; X-B Wang; K-Y Ding; J Tong; B-L Tang; C-Y Zhou; W Yao; C-C Zheng; K-D Song; X-Y Zhu; W Wei; Y Wang
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

5.  Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice.

Authors:  Duncan Purtill; Katherine Smith; Sean Devlin; Richard Meagher; Joann Tonon; Marissa Lubin; Doris M Ponce; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Cladd E Stevens; Juliet N Barker
Journal:  Blood       Date:  2014-09-02       Impact factor: 22.113

6.  Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Authors:  Sarah Anand; Samantha Thomas; Kelly Corbet; Cristina Gasparetto; Gwynn D Long; Richard Lopez; Ashley K Morris; David A Rizzieri; Keith M Sullivan; Anthony D Sung; Stefanie Sarantopoulos; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-17       Impact factor: 5.742

7.  Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study.

Authors:  Susan K Seo; Kun Xiao; Yao-Ting Huang; Ubonvan Jongwutiwes; Dick Chung; Molly Maloy; Sergio Giralt; Juliet N Barker; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  J Infect       Date:  2014-06-12       Impact factor: 6.072

8.  Sustained donor engraftment in recipients of double-unit cord blood transplantation is possible despite donor-specific human leukoctye antigen antibodies.

Authors:  Parastoo B Dahi; Jonathan Barone; Sean M Devlin; Courtney Byam; Marissa Lubin; Doris M Ponce; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Susan H Hsu; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-23       Impact factor: 5.742

9.  A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation.

Authors:  G S Hobbs; N Kaur; P Hilden; D Ponce; C Cho; H R Castro-Malaspina; S Giralt; J D Goldberg; A A Jakubowski; E B Papadopoulos; C Sauter; G Koehne; J Yahalom; S Delvin; J N Barker; M-A Perales
Journal:  Bone Marrow Transplant       Date:  2016-03-14       Impact factor: 5.483

10.  Short- and long-term outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peritransplant period.

Authors:  Sebastian Mayer; Stephen M Pastores; Elyn Riedel; Molly Maloy; Ann A Jakubowski
Journal:  Leuk Lymphoma       Date:  2016-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.